Sunstone Life Science Fund III portfolio Company Cantargia AB has announced that the European Patent Office (“EPO”) has granted the company’s patent application on the product candidate CAN04. CAN04 is targeted against the molecule IL1RAP expressed in a large number of cancer diseases. The formal approval follows the intention to grant that EPO issued in April 2017.

The patent application with number 15714603.6 which was granted by the EPO, concerns the company’s product candidate CAN04. The patent protects CAN04 both as a substance as well for cancer treatment. The patent gives protection in Europe until 2035. In addition to the patent granted in Europe, a notice of allowance was obtained in the USA in June 2017. The application has also been submitted in a large number of additional territories such as Japan and China.

One of the highlights of the Emerging Technology Showcase Area at the European Society of Cardiology Congress in Barcelona, will be Swedish/Danish Acarix AB’s (publ) (“Acarix”) CADScor®System, an advanced, easy to use, frontline test to rule out Coronary Artery Disease (CAD) with high accuracy.  Initial study results released earlier this year show that the Danish Design Award winning CADScor®System non-invasively rules out CAD with 97% negative predictive value. Following this, the CADScor®System has been commercially launched in the Nordics and Germany to both private and public cardiology centers.

In addition to seeing demonstrations of the CADScor®System on booth F140 in the Emerging Technology Showcase Area, delegates will also be able to learn about study results from Principal Investigator Morten Böttcher, MD PhD FESC and Simon Winther, MD PhD, Department of Cardiology, Herning Hospital, Denmark.

Sunstone Life Science Fund II portfolio Company VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that the first clinical data in glioblastoma with its lead product candidate, oral VXM01, are being presented at the upcoming American Society of Clinical Oncology (ASCO) 2017 Annual Meeting being held June 2-6, 2017 in Chicago, IL, USA.

Sunstone Life Science Fund II portfolio company Orphazyme ApS, a Danish biotech company developing novel therapies for the treatment of protein misfolding diseases, has announced the completion of enrolment for its lead program within Niemann-Pick type C disease. Niemann-Pick type C disease (NPC) is one of several fatal lysosomal storage diseases and is affecting around 1 in 150,000 newborns. Although symptom onset and progression is highly variable, NPC is most often diagnosed in childhood and adolescence. Impaired breakdown and recycling of lipids in cells of affected individuals leads to malfunction and demise of cells in the brain and other organs, which results in seizures, progressive loss of muscle control and intellectual capacity.

Sunstone Life Science Fund II portfolio company VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that it has entered into a collaboration agreement with Merck KGaA, Darmstadt, Germany, a leading science and technology company which in the US and Canada operates as EMD Serono, and Pfizer Inc. (NYSE: PFE) to evaluate avelumab*, a human anti-PD-L1 antibody, in combination with VAXIMM’s VXM01. VXM01 is an investigational oral T-cell immunotherapy designed to activate T-cells to attack the tumor vasculature, and, in several tumor types, attack cancer cells directly. Under the terms of the agreement, VAXIMM will be responsible for conducting two open-label Phase I/II trials – one in glioblastoma and one in metastatic colorectal cancer.

* Avelumab is under clinical investigation for treatment of glioblastoma and metastatic colorectal cancer and has not been demonstrated to be safe and effective for these indications. There is no guarantee that avelumab will be approved for glioblastoma and metastatic colorectal cancer by any health authority worldwide.